Page 2 of 31

LISTING OF CLAIMS

The listing of claims will replace all prior versions, and listings of claims in the application:

1. (Currently Amended) A compound selected from Formula Ia, Ib, Ie, and Id and Ie:

in which:

n is selected from 0, 1 and 2; m is selected from 0, 1, 2 and 3;

W is selected from $-NR_4-$, -S-, -O-, -S(O)- and $-S(O)_2-$; wherein R_4 is selected from hydrogen and C_{1-6} alkyl;

 R_1 is selected from $C_{6\cdot10}$ aryl- $C_{0\cdot4}$ alkyl, $C_{5\cdot10}$ heteroaryl- $C_{0\cdot4}$ alkyl, $C_{3\cdot12}$ cycloalkyl- $C_{0\cdot4}$ alkyl and $C_{3\cdot8}$ heterocycloalkyl- $C_{0\cdot4}$ alkyl; wherein any arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl of R_1 is optionally substituted by 1 to 3 radicals independently selected from halo, nitro, cyano, $C_{6\cdot10}$ aryl, $C_{5\cdot10}$ heteroaryl, $C_{3\cdot12}$ cycloalkyl, $C_{3\cdot8}$ heterocycloalkyl, $C_{1\cdot6}$ alkyl, $C_{1\cdot6}$ alkoxy, halo-substituted- $C_{1\cdot6}$ alkyl, halo-substituted- $C_{1\cdot6}$ alkoxy, – XNR_5R_5 , – $XNR_5XNR_5R_5$, – XNR_5XOR_5 , – XOR_5 , – XSR_5 , – $XS(O)R_5$, – $XS(O)_2R_5$, – $XC(O)NR_5R_5$, – $XOXR_6$ and – $XC(O)R_6$; wherein X is a bond or $C_{1\cdot6}$ alkylene; R_5 is selected from hydrogen, $C_{1\cdot6}$ alkyl and $C_{3\cdot12}$ cycloalkyl- $C_{0\cdot4}$ alkyl; and R_6 is selected from $C_{3\cdot8}$ heterocycloalkyl- $C_{0\cdot4}$ alkyl and $C_{5\cdot10}$ heteroaryl- $C_{0\cdot4}$ alkyl optionally substituted by 1 to 3 radicals selected from $C_{1\cdot6}$ alkyl and –C(O)OH; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl substituent of R_1 is further optionally substituted by 1 to 5 radicals independently selected from $C_{1\cdot6}$ alkyl and $C_{1\cdot6}$ alkoxy;

Response Date: May 14, 2010

Page 3 of 31

R₂ is selected from C_{6-10} aryl- C_{0-4} alkyl, C_{5-10} heteroaryl- C_{0-4} alkyl, and C_{3-12} cycloalkyl- C_{0-4} alkyl and C_{3-8} heteroeyeloalkyl- C_{0-4} alkyl; wherein any arylalkyl, heteroarylalkyl, or cycloalkylalkyl or heteroeyeloalkylalkyl of R₂ is optionally substituted by 1 to 3 radicals independently selected from halo, nitro, cyano, C_{1-6} alkyl, C_{1-6} alkenyl, C_{1-6} alkynyl, C_{1-6} alkoxy, halo-substituted- C_{1-6} alkoxy, C_{3-8} heteroaryl C_{0-4} alkyl, $-XNR_5R_5$, $-XC(0)R_5$, $-XSR_5$, $-XS(0)_2R_5$, $-XSNR_5R_5$, $-XS(0)_2NR_5R_5$, $-XS(0)_2NR_5R_5$, $-XC(0)OR_5$, $-XC(0)OR_5$, $-XC(0)NR_5XNR_5R_5$, $-XC(0)NR_5XNR_5C(0)OR_5$, $-XC(0)NR_5XNR_5C(0)OR_5$, $-XC(0)NR_5XNR_5C(0)OR_5$, $-XC(0)NR_5XNR_5C(0)OR_5$, $-XC(0)NR_5XNR_5C(0)R_5$, $-XC(0)NR_5XNR_5$; wherein X is a bond or C_{1-6} alkylene; and C_{3-10} is selected from hydrogen, C_{1-6} alkyl and C_{3-10} heteroaryl- C_{0-4} alkyl optionally substituted by 1 to 3 radicals selected from C_{1-6} alkyl and -C(0)OH; and C_{3-10} is selected from halo and cyano;

 R_3 is selected from halo, hydroxy, $-XSR_5$, $-XS(O)R_5$, $-XS(O)_2R_5$, $-XC(O)R_5$ and $-XC(O)OR_5$; wherein X is a bond or $C_{1\text{-}6}$ alkylene; and R_5 is selected from hydrogen, $C_{1\text{-}6}$ alkyl and $C_{3\text{-}12}$ cycloalkyl- $C_{0\text{-}4}$ alkyl; and the pharmaceutically acceptable salts, hydrates, solvates, isomers and prodrugs thereof.

- 2. (Original) The compound of claim 1 in which:
- $W \qquad \text{is selected from -NR}_{4}\text{- and -O-; wherein }R_{4} \text{ is selected from hydrogen and }C_{1}. \\$
- R_1 is selected from C_{6-10} aryl- C_{0-4} alkyl and C_{5-10} heteroaryl- C_{0-4} alkyl; wherein any arylalkyl and heteroarylalkyl of R_1 is optionally substituted by 1 to 3 radicals independently selected from halo, nitro, C_{5-10} heteroaryl, C_{1-6} alkyl, C_{1-6} alkoxy, halo-substituted- C_{1-6} alkyl, -XNR $_5$ R $_5$, -XOR $_5$, -XSR $_5$, -XNR $_5$ XNR $_5$ R $_5$, -XNR $_5$ XOR $_5$, -XC(O)NR $_5$ R $_5$, -XOXR $_6$ and -XC(O)R $_6$; wherein X is a bond or C_{1-6} alkylene; R_5 is selected from hydrogen, C_{1-6} alkyl and C_{3-12} cycloalkyl- C_{0-4} alkyl; and R_6 is selected from C_{3-8} heterocycloalkyl- C_{0-4} alkyl and C_{5-10} heteroaryl- C_{0-4} alkyl optionally substituted by 1 to 3 radicals selected from C_{1-6} alkyl and -C(O)OH; wherein any heteroaryl substituent of R_1 is further optionally substituted by 1 to 5 C_{1-6} alkyl radicals;
- R_2 is selected from $C_{6\text{-}10}$ aryl- $C_{0\text{-}4}$ alkyl and $C_{5\text{-}10}$ heteroaryl- $C_{0\text{-}4}$ alkyl; wherein any arylalkyl or heteroarylalkyl of R_2 is optionally substituted by 1 to 3 radicals independently

Response Date: May 14, 2010

Page 4 of 31

selected from halo, nitro, cyano, C_{1-6} alkyl, C_{1-6} alkenyl, C_{1-6} alkoxy, halo-substituted- C_{1-6} alkyl, C_{3-8} heteroaryl C_{0-4} alkyl, $-XNR_5R_5$, $-XOR_5$, $-XSR_5$, $-XS(O)_2NR_5R_5$, $-XC(O)OR_5$, $-XOC(O)R_5$, $-XC(O)NR_5XNR_5R_5$, $-XC(O)NR_5XC(O)OR_5$, $-XC(O)NR_5XNR_5C(O)R_5$, $-XC(O)NR_5XNR_5C(O)R_5$, $-XC(O)NR_5XNR_5C(O)R_5$, $-XC(O)NR_5XNR_5C(O)R_5$, $-XC(O)NR_5XR_7$; wherein X is a bond or X0 is selected from hydrogen, X1 is selected from X2 is selected from X3 is selected from X4 is selected from X5 is selected from X5 is selected from X6 is selected from X7 is cyano; and

- R_3 is selected from halo, hydroxy, $-XC(O)R_5$ and $-XC(O)OR_5$; wherein X is a bond or C_{1-6} alkylene; and R_5 is selected from hydrogen, C_{1-6} alkyl and C_{3-12} cycloalkyl- C_{0-4} alkyl.
- 3. (Original) The compound of claim 1 in which W is selected from –NH– and –O–; and R₁ is selected from phenyl, benzyl, 5,6,7,8-tetrahydro-naphthalenyl, benzo[1,3]dioxolyl, 1H-indazol-7-yl, indan-4-yl and 1H-indolyl; wherein any arylalkyl and heteroarylalkyl of R₁ is optionally substituted by 1 to 3 radicals independently selected from methoxy, methyl, amino, halo, hydroxymethyl, hydroxy, quinoxalinyl, ethyl, pyridinyl, methoxy-phenyl, piperazinyl-carbonyl, ethyl-(2-hydroxy-ethyl)-amino 2-(4-methyl-piperazin-1-yl)-ethoxy, formamyl, isopropyl, methyl-sulfanyl, tri-fluoro-methyl, ethoxy, 3-isopropylamino-propylamino, dimethyl-amino, morpholino, cyclopropyl-methoxy, butoxy, cycloheptyl-oxy and 1,4,5,7-tetramethyl-pyrrolo[3,4-d]pyridazinyl.
- 4. (Original) The compound of claim 1 in which R₂ is selected from pyridinyl, phenyl, thiazolyl, pyridinyl-methyl, pyridinyl-ethyl, thiophenyl, benzyl, quinolinyl, 7-oxo-5,6,7,8-tetrahydro-naphthalenyl, naphthyl and pyrimidinyl; wherein any arylalkyl or heteroarylalkyl of R₂ is optionally substituted by 1 to 3 radicals independently selected from halo, nitro, cyano, methyl, propyl-sulfamoyl, methyl-sulfamoyl, methoxy, methyl-carboxy, 2-dimethylamino-ethyl-formamyl, carboxy, amino, cyano-ethyl, cyano-methyl, ethenyl, tri-fluoro-methyl, hydroxy-methyl, ethyl, methyl-sulfanyl, butyl, isobutyl, carboxy-methyl-formamidyl, 1-carboxy-ethyl-formamidyl, carboxy-ethyl, amino-ethyl-formamidyl, amino-propyl-formamidyl, dimethyl-amino-butyl-formamidyl, dimethyl-formamidyl, ethyl-formamidyl, ethyl-formamidyl, methyl-formamidyl, 2-(2-

Response Date: May 14, 2010

Page 5 of 31

dimethylamino-ethylcarbamoyl)-ethyl, 2-(2-dimethylamino-formamidyl)-ethyl, 2-(amino-ethylformamidyl)-ethyl, 2-(amino-propyl-formamidyl)-ethyl, 2-(propyl-formamidyl)-ethyl, aminopropyl-formamidyl-methyl, 2-(methyl-amino-carbamoyl)-ethyl, 2-(ethyl-amino-carbamoyl)-ethyl, morpholino-ethyl-formamidyl, morpholino-carbonyl-methyl, amino-ethyl-formamidyl-methyl, cyclobutyl-formamidyl, methyl-formamidyl-methyl, dimethyl-formamidyl-methyl, hydroxyethyl-formamidyl-methyl, hydroxy-propyl-formamidyl-methyl, N,N-bis-(3-hydroxy-propyl)formamidyl, cyclopentyl-formamidyl, isobutyl-formamidyl, isobutyl-formamidyl-methyl, cyclopentyl-formamidyl-methyl, cyano-ethyl-formamidyl, cyano-methyl-formamidyl, pyrrolidinyl-ethyl-formamidyl, 2-(isobutyl-formamidyl)-ethyl, 1H-tetrazolyl, 2-(1H-tetrazol-5yl)-ethyl, 2-(1H-tetrazol-5-yl)-methyl, 2-(1-methyl-1H-tetrazol-5-yl)-methyl, acetyl-amino, cyclopropyl-formamidyl-methyl, hydroxy-ethyl-formamidyl, hydroxy-propyl-formamidyl, propyl-formamidyl-methyl, ethoxy-propyl-formamidyl, acetyl-amino-ethyl-formamidyl, 1methyl-piperidin-4-yl-formamidyl, morpholino-carbonyl-ethyl, methoxy-carbonyl-methyl, methoxy-carbonyl-ethyl-formamidyl, methoxy-carbonyl-ethyl-formamidyl-methyl, methoxycarbonyl-methyl-formamidyl-methyl, methoxy-carbonyl-methyl-formamidyl, 4-aminocyclohexyl-formamidyl, 4-amino-cyclohexyl-formamidyl-methyl, acetyl-amino-ethylformamidyl-methyl, ethoxy-propyl-formamidyl-methyl, methoxy-carbonyl-ethyl, 1-formylpyrrolidin-2-yl-carboxylic acid, (1-carboxy-3-methyl-butyl)-formamidyl, 2-(methoxy-carbonylmethyl-formamidyl)-ethyl, 1-carboxy-(2,2-dimethyl-propyl)-formamidyl, 3-tert-butoxycarbonylamino-propyl-formamidyl, acetoxy-methyl and 1-carboxy-ethyl-formamidyl.

- 5. (Currently Amended) The compound of claim 1 in which n is 0 or 1; $\frac{1}{m}$ is 0 or 1; \frac
 - 6. (Original) The compound of claim 1 of Formula Ig:

$$H_3CO$$
 H_3CO
 H_3CO
 H_3CO
 H_3CO
 H_3CO
 H_3CO
 H_3
 H_3CO
 H_3
 H_3CO
 H_3
 H_3
 H_3

Response Date: May 14, 2010

Page 6 of 31

in which R₂ is selected from pyridinyl, phenyl, thiazolyl, pyridinyl-methyl, pyridinylethyl, thiophenyl, benzyl, quinolinyl, 7-oxo-5,6,7,8-tetrahydro-naphthalenyl, naphthyl and pyrimidinyl; wherein any arylalkyl or heteroarylalkyl of R₂ is optionally substituted by 1 to 3 radicals independently selected from halo, nitro, cyano, methyl, propyl-sulfamoyl, methylsulfamoyl, methoxy, methyl-carboxy, 2-dimethylamino-ethyl-formamyl, carboxy, amino, cyanoethyl, cyano-methyl, ethenyl, tri-fluoro-methyl, hydroxy-methyl, ethyl, methyl-sulfanyl, butyl, isobutyl, carboxy-methyl-formamidyl, 1-carboxy-ethyl-formamidyl, carboxy-ethyl, amino-ethylformamidyl, amino-propyl-formamidyl, dimethyl-amino-ethyl-formamidyl, dimethyl-aminopropyl-formamidyl, dimethyl-amino-butyl-formamidyl, methyl-formamidyl, ethyl-formamidyl, ethyl-formamidyl-methyl, 2-(2-dimethylamino-ethylcarbamoyl)-ethyl, 2-(2-dimethylaminoformamidyl)-ethyl, 2-(amino-ethyl-formamidyl)-ethyl, 2-(amino-propyl-formamidyl)-ethyl, 2-(propyl-formamidyl)-ethyl, amino-propyl-formamidyl-methyl, 2-(methyl-amino-carbamoyl)ethyl, 2-(ethyl-amino-carbamoyl)-ethyl, morpholino-ethyl-formamidyl, morpholino-carbonylmethyl, amino-ethyl-formamidyl-methyl, cyclobutyl-formamidyl, methyl-formamidyl-methyl, dimethyl-formamidyl-methyl, hydroxy-ethyl-formamidyl-methyl, hydroxy-propyl-formamidylmethyl, N,N-bis-(3-hydroxy-propyl)-formamidyl, cyclopentyl-formamidyl, isobutyl-formamidyl, isobutyl-formamidyl-methyl, cyclopentyl-formamidyl-methyl, cyano-ethyl-formamidyl, cyanomethyl-formamidyl, pyrrolidinyl-ethyl-formamidyl, 2-(isobutyl-formamidyl)-ethyl, 1H-tetrazolyl, 2-(1H-tetrazol-5-yl)-ethyl, 2-(1H-tetrazol-5-yl)-methyl, 2-(1-methyl-1H-tetrazol-5-yl)-methyl, acetyl-amino, cyclopropyl-formamidyl-methyl, hydroxy-ethyl-formamidyl, hydroxy-propylformamidyl, propyl-formamidyl-methyl, ethoxy-propyl-formamidyl, acetyl-amino-ethylformamidyl, 1-methyl-piperidin-4-yl-formamidyl, morpholino-carbonyl-ethyl, methoxycarbonyl-methyl, methoxy-carbonyl-ethyl-formamidyl, methoxy-carbonyl-ethyl-formamidylmethyl, methoxy-carbonyl-methyl-formamidyl-methyl, methoxy-carbonyl-methyl-formamidyl, 4amino-cyclohexyl-formamidyl, 4-amino-cyclohexyl-formamidyl-methyl, acetyl-amino-ethylformamidyl-methyl, ethoxy-propyl-formamidyl-methyl, methoxy-carbonyl-ethyl, 1-formylpyrrolidin-2-yl-carboxylic acid, (1-carboxy-3-methyl-butyl)-formamidyl, 2-(methoxy-carbonylmethyl-formamidyl)-ethyl, 1-carboxy-(2,2-dimethyl-propyl)-formamidyl, 3-tert-butoxycarbonylamino-propyl-formamidyl, acetoxy-methyl and 1-carboxy-ethyl-formamidyl.

Response Date: May 14, 2010

Page 7 of 31

- 7. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 in combination with a pharmaceutically acceptable excipient.
- 8. (Original) A method for treating a disease in an animal in which inhibition of kinase activity can prevent, inhibit or ameliorate the pathology and/or symptomology of the disease, which method comprises administering to the animal a therapeutically effective amount of a compound of Claim 1.
- 9. (Original) The method of claim 7 in which the kinase is selected from FAK, Abl, BCR-Abl, PDGF-R, c-Kit, NPM-ALK, Flt-3, JAK2 and c-Met.
- 10. (Canceled) The use of a compound of claim 1 in the manufacture of a medicament for treating a disease in an animal in which the kinase activity of FAK, Abl, BCR-Abl, PDGF-R, c-Kit, NPM-ALK, Flt-3, JAK2 and/or c-Met contributes to the pathology and/or symptomology of the disease.
 - 11. (New) The compound of claim 1 selected from:

Application No.: 10/589,099 Ha-Soon Choi, *et al*. Response Date: May 14, 2010 Page 8 of 31

HZ Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	N N N N N N N N N N N N N N N N N N N
	N N F F F
HN N O=S-NH MeO	
HN N	THE TOTAL PROPERTY OF THE PROP
HN N N N N N N N N N N N N N N N N N N	HN N N N N N N N N N N N N N N N N N N

Application No.: 10/589,099 Ha-Soon Choi, *et al*. Response Date: May 14, 2010 Page 9 of 31

DH N N N N N N N N N N N N N N N N N N N	NH HN CH OH
OH HN N N	
HN N O S O O O O O O O O O O O O O O O O	HN N N N N N N N N N N N N N N N N N N
HN N N N N N N N N N N N N N N N N N N	Z==Z N Z==Z
	HAZ Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z

Application No.: 10/589,099 Ha-Soon Choi, *et al*. Response Date: May 14, 2010 Page 10 of 31

	N N N N N N N N N N N N N N N N N N N
H N N N N N N N N N N N N N N N N N N N	HNNNN
N N N N CI	
B HN N	HN

Application No.: 10/589,099 Ha-Soon Choi, *et al*. Response Date: May 14, 2010 Page 11 of 31

HN N N N N N N N N N N N N N N N N N N	N N H HN O
	NH NH ₂
HNNN	NO N
HN N N N N N N N N N N N N N N N N N N	
	N NH NH O

Application No.: 10/589,099 Ha-Soon Choi, *et al*. Response Date: May 14, 2010 Page 12 of 31

NH NH	N N N N N N N N N N N N N N N N N N N
HN N	Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z
HN N N N N N N N N N N N N N N N N N N	X Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y
NH NN CI	NH NH ₂
HN NH ₂	HN N N N N N N N N N N N N N N N N N N

Application No.: 10/589,099 Ha-Soon Choi, *et al*. Response Date: May 14, 2010 Page 13 of 31

H N N N N N N N N N N N N N N N N N N N	N NH
	HE TO THE TOTAL PROPERTY OF THE TOTAL PROPER
N N N N N N N N N N N N N N N N N N N	NH NH ₂
N N N N N N N N N N N N N N N N N N N	N N N N N N N N N N N N N N N N N N N
HN N	NH H _S N

Application No.: 10/589,099 Ha-Soon Choi, *et al*. Response Date: May 14, 2010 Page 14 of 31

HN N N N N N N N N N N N N N N N N N N	NH NH NH
HO HO NO	N OH OH
HNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN	N NH O
	NH NH NH ₂
HN N N N N N N N N N N N N N N N N N N	HN

Page 14 of 31

Application No.: 10/589,099 Ha-Soon Choi, *et al*. Response Date: May 14, 2010 Page 15 of 31

HN N N N N N N N N N N N N N N N N N N	HN N
	HN N N N N N N N N N N N N N N N N N N
HN N N N N N N N N N N N N N N N N N N	THE
HN N O S O	N N F F

Application No.: 10/589,099 Ha-Soon Choi, *et al*. Response Date: May 14, 2010 Page 16 of 31

HN N N NH O	HNN
F F N N N N N N N N N N N N N N N N N N	HNNNN
HZ Z	
N N N N N N N N N N N N N N N N N N N	

Application No.: 10/589,099 Ha-Soon Choi, *et al*. Response Date: May 14, 2010 Page 17 of 31

Br HN N	N N N N N N N N N N N N N N N N N N N
HN N	NH NH
	N N N N N N N N N N N N N N N N N N N
HN 2 2 2 2 2	N N N N N N N N N N N N N N N N N N N
NH NN N	N N N N N N N N N N N N N N N N N N N

Application No.: 10/589,099 Ha-Soon Choi, *et al.* Response Date: May 14, 2010 Page 18 of 31

Application No.: 10/589,099 Ha-Soon Choi, *et al*. Response Date: May 14, 2010 Page 19 of 31

	NH HN
HN N	
CI N N HO	NH O
N N N N N N N N N N N N N N N N N N N	NH NH
HN HN H	HN

Application No.: 10/589,099 Ha-Soon Choi, *et al*. Response Date: May 14, 2010 Page 20 of 31

NH NH	HNNNN
O H N N N N N N N N N N N N N N N N N N	N N N N N N N N N N N N N N N N N N N
N N N N N N N N N N N N N N N N N N N	
N N N N N N N N N N N N N N N N N N N	N N H HN CH,
NH HN OH	NH NH

Application No.: 10/589,099 Ha-Soon Choi, *et al*. Response Date: May 14, 2010 Page 21 of 31

HO OH NO	N N N N N N N N N N N N N N N N N N N
N N N HN HO O	
N N N N N N N N N N N N N N N N N N N	
N N N N N N N N N N N N N N N N N N N	N N N N N N N N N N N N N N N N N N N
N N H HN NH ₂	N N N N N N N N N N N N N N N N N N N

Application No.: 10/589,099 Ha-Soon Choi, *et al.* Response Date: May 14, 2010 Page 22 of 31

Application No.: 10/589,099 Ha-Soon Choi, *et al*. Response Date: May 14, 2010 Page 23 of 31

NH HN H	N N C C C C C C C C C C C C C C C C C C
HN N HN	N N H N H N N H N N N N N N N N N N N N
NH HN N	
NH HO	HZ N N N N N N N N N N N N N N N N N N N
N N N N N N N N N N N N N N N N N N N	N N N N N N N N N N N N N N N N N N N

Application No.: 10/589,099 Ha-Soon Choi, *et al.* Response Date: May 14, 2010 Page 24 of 31

Application No.: 10/589,099 Ha-Soon Choi, *et al*. Response Date: May 14, 2010 Page 25 of 31

N N N N N N N N N N N N N N N N N N N	N N N N N N N N N N N N N N N N N N N
N N N N N N N N N N N N N N N N N N N	
HN N N N N N N N N N N N N N N N N N N	
HN N N N N N N N N N N N N N N N N N N	N N S N N N N N N N N N N N N N N N N N

Application No.: 10/589,099 Ha-Soon Choi, *et al*. Response Date: May 14, 2010 Page 26 of 31

	N N N N N N N N N N N N N N N N N N N
N H H N H N N N N N N N N N N N N N N N	N N N N N N N N N N N N N N N N N N N
N N N N N N N N N N N N N N N N N N N	
N N N HN N N	

Application No.: 10/589,099 Ha-Soon Choi, *et al*. Response Date: May 14, 2010 Page 27 of 31

N N N N N N N N N N N N N N N N N N N	
N N N N N N N N N N N N N N N N N N N	N N N N N N N N N N N N N N N N N N N
N N N HC-N	
HNNNN	
HN H	

Application No.: 10/589,099 Ha-Soon Choi, *et al*. Response Date: May 14, 2010 Page 28 of 31

12. (New) A compound selected from:

Application No.: 10/589,099 Ha-Soon Choi, *et al.* Response Date: May 14, 2010 Page 29 of 31